Cytex Awarded CRP Award for First-In-Human Pilot Trial

Cytex is thrilled to announce the receipt of a Commercialization Readiness Pilot Program Award from the National Institute of Health entitled “Cartilage Regeneration with Tunable Inflammation Resistance.”  The goal of this project is to prepare for and then conduct a First-In-Human pilot clinical trial that will test the safety of Cytex’s innovative hip implant.  Cytex is grateful for the ongoing support of the NIH.  Research conducted in this project is supported by the National Institute On Aging of the National Institutes of Health under Award Number R44AG059310.